Alnylam Pharmaceuticals, Inc. (ALNY)
309.87
-10.26
(-3.20%)
USD |
NASDAQ |
Apr 17, 12:14
Alnylam Pharmaceuticals Cash from Investing (Quarterly) : -37.17M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | -6.146B |
| Eli Lilly & Co. | -2.802B |
| Ionis Pharmaceuticals, Inc. | -419.50M |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Sarepta Therapeutics, Inc. | 96.21M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 163.56M |
| Cash from Financing (Quarterly) | 45.32M |
| Free Cash Flow | 465.38M |
| Free Cash Flow Per Share (Quarterly) | 1.029 |
| Free Cash Flow to Equity (Quarterly) | -55.23M |
| Free Cash Flow to Firm (Quarterly) | 289.89M |
| Free Cash Flow Yield | 1.13% |